Cardiovascular Disease Progression: A Target for Therapy?

Research output: Contribution to journalReview article

Abstract

Clinical research aimed at preventing cardiovascular disease has focused on the effect of interventions to reduce risk factors on the incidence of future morbid events. Disease progression, which likely serves as a necessary prerequisite for morbid events, has not served as a target for therapy. The Rasmussen Center at the University of Minnesota has, for the past 18 years, been performing a noninvasive cardiovascular evaluation in individuals with no history of cardiovascular disease. The studies, performed in 1 hour in one room, provide a comprehensive noninvasive assessment of the severity of functional and structural abnormalities in the small arteries, the large arteries and the left ventricle, the target organs for most cardiovascular morbid events. Preliminary follow-up data have revealed a striking relationship between the Disease Score, which represents the sum of the abnormal tests, and the risk of future morbid events. In order to develop strategies to prolong cardiovascular disease-free life expectancy, studies in early stages of disease aimed at slowing disease progression should be encouraged.

Original languageEnglish (US)
Pages (from-to)1170-1173
Number of pages4
JournalAmerican Journal of Medicine
Volume131
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Disease Progression
Cardiovascular Diseases
Arteries
Life Expectancy
Heart Ventricles
Therapeutics
Incidence
Research

Keywords

  • Cardiovascular morbid events
  • Early cardiovascular disease
  • Noninvasive testing
  • Risk factors

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

Cardiovascular Disease Progression : A Target for Therapy? / Cohn, Jay N.

In: American Journal of Medicine, Vol. 131, No. 10, 01.10.2018, p. 1170-1173.

Research output: Contribution to journalReview article

@article{56e7a892995d4fd2b7f1a4c6fae0abb8,
title = "Cardiovascular Disease Progression: A Target for Therapy?",
abstract = "Clinical research aimed at preventing cardiovascular disease has focused on the effect of interventions to reduce risk factors on the incidence of future morbid events. Disease progression, which likely serves as a necessary prerequisite for morbid events, has not served as a target for therapy. The Rasmussen Center at the University of Minnesota has, for the past 18 years, been performing a noninvasive cardiovascular evaluation in individuals with no history of cardiovascular disease. The studies, performed in 1 hour in one room, provide a comprehensive noninvasive assessment of the severity of functional and structural abnormalities in the small arteries, the large arteries and the left ventricle, the target organs for most cardiovascular morbid events. Preliminary follow-up data have revealed a striking relationship between the Disease Score, which represents the sum of the abnormal tests, and the risk of future morbid events. In order to develop strategies to prolong cardiovascular disease-free life expectancy, studies in early stages of disease aimed at slowing disease progression should be encouraged.",
keywords = "Cardiovascular morbid events, Early cardiovascular disease, Noninvasive testing, Risk factors",
author = "Cohn, {Jay N}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.amjmed.2018.03.032",
language = "English (US)",
volume = "131",
pages = "1170--1173",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Cardiovascular Disease Progression

T2 - A Target for Therapy?

AU - Cohn, Jay N

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Clinical research aimed at preventing cardiovascular disease has focused on the effect of interventions to reduce risk factors on the incidence of future morbid events. Disease progression, which likely serves as a necessary prerequisite for morbid events, has not served as a target for therapy. The Rasmussen Center at the University of Minnesota has, for the past 18 years, been performing a noninvasive cardiovascular evaluation in individuals with no history of cardiovascular disease. The studies, performed in 1 hour in one room, provide a comprehensive noninvasive assessment of the severity of functional and structural abnormalities in the small arteries, the large arteries and the left ventricle, the target organs for most cardiovascular morbid events. Preliminary follow-up data have revealed a striking relationship between the Disease Score, which represents the sum of the abnormal tests, and the risk of future morbid events. In order to develop strategies to prolong cardiovascular disease-free life expectancy, studies in early stages of disease aimed at slowing disease progression should be encouraged.

AB - Clinical research aimed at preventing cardiovascular disease has focused on the effect of interventions to reduce risk factors on the incidence of future morbid events. Disease progression, which likely serves as a necessary prerequisite for morbid events, has not served as a target for therapy. The Rasmussen Center at the University of Minnesota has, for the past 18 years, been performing a noninvasive cardiovascular evaluation in individuals with no history of cardiovascular disease. The studies, performed in 1 hour in one room, provide a comprehensive noninvasive assessment of the severity of functional and structural abnormalities in the small arteries, the large arteries and the left ventricle, the target organs for most cardiovascular morbid events. Preliminary follow-up data have revealed a striking relationship between the Disease Score, which represents the sum of the abnormal tests, and the risk of future morbid events. In order to develop strategies to prolong cardiovascular disease-free life expectancy, studies in early stages of disease aimed at slowing disease progression should be encouraged.

KW - Cardiovascular morbid events

KW - Early cardiovascular disease

KW - Noninvasive testing

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=85048712559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048712559&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2018.03.032

DO - 10.1016/j.amjmed.2018.03.032

M3 - Review article

VL - 131

SP - 1170

EP - 1173

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 10

ER -